Spirulina and adrenal insufficiency: Addison's disease, hydrocortisone interactions, and electrolytes

Adrenal insufficiency: primary vs secondary

Primary AI (Addison’s): Autoimmune destruction of all three adrenal cortical zones — zona glomerulosa (aldosterone), zona fasciculata (cortisol), and zona reticularis (DHEA). The result is cortisol deficiency, aldosterone deficiency (causing sodium wasting and potassium retention), and DHEA deficiency (contributing to fatigue and low libido). Anti-21-hydroxylase antibodies are present in >90% of cases.
Secondary AI: ACTH deficiency from pituitary disease (tumour, apoplexy, hypophysitis) or iatrogenic hypothalamic-pituitary-adrenal (HPA) suppression from exogenous corticosteroids (>20 mg/day prednisolone or equivalent for >3 weeks). Only cortisol is deficient (ACTH stimulates cortisol and androgens; aldosterone is regulated by renin-angiotensin independently and is preserved in SAI).

Primary AI (Addison’s): Addison’s is autoimmune but adrenal autoimmunity is not driven by NK cells specifically — it is primarily T cell-mediated (CD4+ and CD8+ against 21-hydroxylase). The NK stimulation concern is lower than in conditions where NK cells are primary effectors (e.g., alopecia areata, PBC). However, Addison’s often coexists with other autoimmune conditions (polyglandular autoimmune syndrome type II: Hashimoto’s, type 1 diabetes, vitiligo) — assess NK concern in the context of all comorbidities.
Secondary AI from steroid withdrawal: If secondary AI results from long-term immunosuppressive corticosteroid use (e.g., prednisolone for RA or IBD), the underlying immunosuppressed condition requires assessment before spirulina (NK concern from the primary condition, not the steroid withdrawal itself).

Hydrocortisone (15–25 mg/day in divided doses) is physiological cortisol replacement in AI. At these doses, it is replacing a deficient hormone, not suppressing the immune system. The immunosuppressive dose of hydrocortisone begins at >100 mg/day. Physiological replacement doses do not meaningfully suppress NK cells; the NK stimulation concern from spirulina is therefore low in AI on physiological steroid replacement.
No CYP pharmacokinetic interaction between spirulina and hydrocortisone. Hydrocortisone is metabolised by CYP3A4; no documented spirulina interaction at CYP3A4.
Fludrocortisone (for aldosterone replacement in primary AI): no pharmacokinetic interaction with spirulina.

Potassium retention in primary AI: Aldosterone deficiency reduces renal potassium excretion, causing hyperkalemia. Spirulina contains approximately 400 mg potassium per 10 g. In Addison’s with aldosterone deficiency (before adequate fludrocortisone replacement): additional dietary potassium from spirulina is a concern. Once fludrocortisone is optimised (with normal serum potassium and sodium): 3–5 g/day spirulina poses modest potassium addition; monitor potassium 2–4 weeks after starting.
Sodium in primary AI: Aldosterone deficiency causes sodium wasting and risk of addisonian crisis in illness (when cortisol and aldosterone demands increase). Spirulina sodium content (100–200 mg/10 g) is low and does not address the sodium-wasting issue. Patients with Addison’s on hot days or during illness should increase dietary sodium — spirulina is not a sodium source for this purpose.
Secondary AI: Aldosterone is intact; electrolyte management is less complex. Standard spirulina potassium content (200 mg/5 g) is unproblematic in SAI with normal renal function and normal baseline potassium.

Fatigue is the dominant symptom in adrenal insufficiency and often persists despite adequate steroid replacement (in 50% of adequately replaced Addison’s patients). Contributing factors include DHEA deficiency, HPA circadian disruption, and frequently concurrent iron deficiency.
Autoimmune polyglandular syndrome type II (Addison’s + autoimmune thyroid disease + potential coeliac disease) increases iron deficiency risk. Check ferritin and transferrin saturation in all Addison’s patients with persistent fatigue. Spirulina iron (2–4 mg/5 g) contributes to dietary iron intake.

Primary AI well-controlled on hydrocortisone + fludrocortisone: 3–5 g/day is appropriate; check serum potassium 2–4 weeks after starting; inform endocrinologist of supplement use
Primary AI with APS-II: assess NK concern in the context of all autoimmune comorbidities (Hashimoto’s is low concern; active type 1 diabetes or other conditions require assessment)
Secondary AI from steroid withdrawal: assess NK concern based on the underlying condition for which steroids were prescribed
Fatigue in AI: iron status + DHEA levels + thyroid function are the most common treatable contributors; spirulina addresses iron; DHEA and thyroid require specialist management